Parathyroid hormone-related protein (PTHrP) plays a primary role in the development of humoral hypercalcemia of malignancy (HHM) that occurs in the majority of patients with adult T-cell leukemia/lymphoma (ATLL) due to human T-cell lymphotropic virus type-1 (HTLV-1) infection. We previously showed that ATLL cells constitutively express high levels of PTHrP via activation of promoters P2 and P3, resulting in HHM. In this study, we characterized a nuclear factor-jB (NF-jB) binding site in the P2 promoter of human PTHrP. Using electrophoretic mobility shift assays, we detected a specific complex in Taxexpressing human T cells composed of p50/c-Rel, and two distinct complexes in ATLL cells consisting of p50/p50 homodimers and a second unidentified protein(s). Chromatin immunoprecipitation assays confirmed in vivo binding of p50 and c-Rel on the PTHrP P2 promoter. Using transient co-transfection with NF-jB expression plasmids and PTHrP P2 luciferase reporter-plasmid, we showed that NF-jB p50/p50 alone and p50/ c-Rel or p50/Bcl-3 cooperatively upregulated the PTHrP P2 promoter. Furthermore, inhibition of NF-jB activity by Bay 11-7082 reduced PTHrP P2 promoter-initiated transcripts in HTLV-1-infected T cells. In summary, the data demonstrated that transcriptional regulation of PTHrP in ATLL cells can be controlled by NF-jB activation and also suggest a Taxindependent mechanism of activation of PTHrP in ATLL.
Introduction
Adult T-cell leukemia/lymphoma (ATLL) is a highly aggressive malignancy of peripheral helper T cells associated with human T-cell lymphotropic virus type-1 (HTLV-1) infection. 1 About 80% of ATLL patients develop humoral hypercalcemia of malignancy (HHM), a life-threatening paraneoplastic syndrome, seen in a wide variety of cancers in addition to ATLL. 2 In HHM, increased circulating parathyroid hormone-related protein (PTHrP) stimulates the parathyroid hormone-1 receptor to induce osteoclastic bone resorption and increase calcium reabsorption in kidneys, resulting in hypercalcemia. 3 In addition to its role in the induction of HHM, PTHrP has been shown to be involved in the regulation of cell proliferation and apoptosis in a wide variety of normal and neoplastic tissues. 4 Transcriptional regulation of the human PTHrP gene is achieved by three distinct promoters identified as P1, P2 and P3. Promoters P1 and P3 (previously called the P2 promoter) contain a typical TATA box, [5] [6] [7] while P2 is a GC-rich promoter region located immediately upstream of exon 3 (also named exon 1c) with the transcription initiation site located 11 nucleotides upstream of the exon 3 splice acceptor site. Several studies have shown that P2/P3 promoter usage is prevalent in many cancers such as breast cancer and bone cancer in addition to HTLV-1-positive and ATLL cells. [8] [9] [10] [11] Furthermore, Brandt et al. 12 reported a preferential usage of P2 over P1 and P3 promoters in different cancer cell lines examined. Although this stimulation and activity of the PTHrP P2 promoter was identified 10 years ago, little is known regarding the transcriptional mechanisms involving cis-acting regulatory sequences within this promoter.
HTLV-1-Tax is a potent transcriptional activator that not only drives the transcription of all HTLV-1 transcripts from the viral LTR but also activates numerous cellular genes through activation of nuclear factor-kB (NF-kB), cyclic AMP response element-binding protein (CREB/ATF) and serum response factor (SRF). [13] [14] [15] NF-kB, a cytokine-inducible family of transcription factors, controls expression of genetic networks important in cell survival, proliferation, inflammation and T-cell transformation. Although tightly regulated in normal T cells, NF-kB is constitutively activated in ATLL and Tax-expressing T cells. 16 While Tax-mediated NF-kB activation serves as a critical step in the induction of T-cell transformation by HTLV-1, the presence of constitutively active NF-kB in freshly isolated ATLL cells that lack detectable Tax expression, implicates a crucial role for NF-kB in the multistep process of leukemogenesis. 17 The NF-kB family is composed of five structurally related protein subunits that can be divided into two groups: (1) p65/ RelA, RelB and c-Rel contain a well-defined transactivation domain; and (2) p50 and p52, which are generated by proteolytic processing from their precursors, p105/NF-kB 1 and p100/NF-kB 2, respectively, and lack transactivation domains. Although the predominant complex in most cells is p50/p65, various dimeric transcription factor complexes can form between the family members. 18 Heterodimers containing p52 or p50 combined with p65, c-Rel or RelB are capable of activating transcription. NF-kB dimers bind target gene regulatory regions through a wide variety of binding sites that generally match a 5 0 -GGGRNNYYCC-3 0 consensus (R, purine; Y, pyrimidine; N, any base). Although their functions often overlap, NF-kB achieves target gene specificity in part through preferential binding of different subunit combinations to numerous similar DNA sequences. 19 NF-kB is expressed in virtually all cell types, but in unstimulated cells the NF-kB homo-and heterodimers are sequestered in the cytoplasm in an inactive form complexed with one of the members of the family of regulatory IkBs, including IkB-a, IkB-b, IkB-g and Bcl-3. IkB molecules are subject to phosphorylation, subsequent degradation and release of active NF-kB upon reception of signals that lead to NF-kB activation. 20 In contrast to IkBa and IkBb, which specifically interact with dimers containing p65 or c-Rel, Bcl-3 specifically interacts with p50 or p52 homodimers and contains N-and C-terminal regions that can act as transactivation domains. 21, 22 Although the cellular function of Bcl-3 is still unclear, various studies have suggested that Bcl-3 acts to increase transcription from NF-kB responsive promoters by either (1) acting as an antirepressor by removing homodimers from the kB sites so that transactivating NF-kB dimers can bind, (2) forming a complex with homodimers at kB sites and acting as a transactivator or (3) enhancing homodimer binding to kB sites. Interestingly, Bcl-3 can enhance p50 or p52 homodimer binding to DNA, without being a stable component of the complex. 23, 24 We have previously reported that the upregulation of PTHrP in ATLL and HTLV-1-infected T cells is mediated by the PTHrP P2 and P3 promoters and that the P3 promoter is regulated by the ETS signaling pathway. The relative PTHrP P2 promoter usage was determined to be 16, 4, 7 and 40 copies (per 10 4 copies of b2M) in HT-1RV, SLB-1, MT-2 and RV-ATL cells, respectively, compared to the 47, 86, 104 and 644 copies (per 10 4 copies of b2M) of total PTHrP. 25 Since ATLL cells display constitutive expression of NF-kB and PTHrP and since sequence analysis of the PTHrP P2 promoter revealed that it contained potential binding sites for NF-kB, we tested in this report the hypothesis that PTHrP gene is a direct target of the transcription factor, NF-kB. We identified an NF-kB binding site within the human PTHrP P2 promoter region that is responsible for NF-kBmediated stimulation of PTHrP promoter activity. We also demonstrated and characterized the formation of different protein complexes on the NF-kB-binding site located within the second promoter (P2) of the human PTHrP gene in HTLV-1-infected and ATLL cells. We present evidence that transactivation of the PTHrP P2 promoter can occur in a subunit-dependent manner by p50/c-Rel and p50/Bcl-3. Finally, we showed that inhibition of NF-kB by the Bay 11-7082 decreased P2 promoterinitiated transcription. Our data demonstrated that transactivation of the PTHrP P2 promoter in HTLV-1-infected and ATLL cells occurs by activation of NF-kB in a Tax-independent manner.
Materials and methods

Sequence analysis
Human, mouse, rat and dog upstream PTHrP P2 promoter sequences (GenBank accession: NM 002820, NM 008970, NM 012636 and NM 001003303, respectively) were analyzed for potential NF-kB binding sites using MatInspector (Genomatix Software GmbH, Munchen, Germany), with 'weight matrices' as the search parameter.
Animals and inoculation
Immunodeficient SCID-NOD (NOD CB17-PRKDC-SCID/J) mice (Jackson Lab, Bar Harbor, ME, USA) were maintained under specific pathogen-free conditions in the animal facility of the College of Veterinary Medicine at The Ohio State University. Male mice aged 5 weeks were used as recipients and injected intraperitoneally with 4 Â 10 7 RV-ATL cells or 3 Â 10 7 Met-1 cells suspended in RPMI 1640 medium. The source of the RV-ATL and Met-1 cells (a kind gift of Dr Feuer and Dr Waldman, respectively) was previously described. 26, 27 RV-ATL cells were harvested by peritoneal lavage 28 days postinoculation. Met-1 cells were harvested from peritoneal tumors approximately 60 days post-inoculation.
Cell lines
MT-2 and SLB-1 are in vitro-transformed HTLV-1-positive cell lines that were obtained by co-cultivating lymphocytes from healthy donors with leukemic cells from ATLL patients. 28 RV-ATL and Met-1 cells are leukemic cells derived from ATLL patients. HT-1RV cells were obtained by superinfecting RV-ATL cells with HTLV-1. 29 IMM-1 cells are interleukin-2 (IL-2)-dependent immortalized cells obtained by in vitro co-cultivation of peripheral blood mononuclear cells from a healthy human donor with irradiated SLB-1 cells. MT-2 and SLB-1 cells were cultured in RPMI 1640 media supplemented with 10% fetal bovine serum (FBS) and the HT-1RV and RV-ATL cells in RPMI 1640 with 20% heat-inactivated (561C, 30 min) FBS, L-glutamine (2 mM), penicillin (50 U/ml) and streptomycin (50 mg/ml) (Invitrogen, Carlsbad, CA, USA) at 371C and 5% CO 2 . NIH 3T3 cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS and 10 mM L-glutamine.
Long-term immortalization assay
Human peripheral blood mononuclear cells were isolated from the blood of healthy donors by centrifugation over Ficoll-Paque (Amersham, Piscataway, NJ, USA) and cultured in RPMI 1640 supplemented with 20% FBS, 10 U/ml IL-2 (Boehringer Mannheim, Mannheim, Germany), 2 mM glutamine and antibiotics. Irradiated SLB-1 cells (10 6 ) were co-cultivated with 2 Â 10 6 freshly isolated peripheral blood mononuclear cells with 10 U/ml IL-2 in 24-well culture plates. The presence of HTLV-1 expression was confirmed by detection of p19 Gag protein in the culture supernatant at weekly intervals using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Zeptometrix, Buffalo, NY). Cells from a donor that continued to proliferate after 30 weeks of co-culture in the presence of exogenous IL-2 were identified as HTLV-1-immortalized cells and were named IMM-1 cells.
Electrophoretic mobility shift assays and supershifts
Nuclear extracts were prepared from RV-ATL, MET-1, HT1-RV, MT-2, SLB-1, IMM-1 and Jurkat cells using the NE-PER Nuclear and Cytoplasmic Extraction Reagents kit (Pierce, Rockford, IL, USA). For NF-kB binding activity on the PTHrP P2 promoter, 1-5 ml of each nuclear extract (7.5 mg of protein) was incubated in 18 ml total reaction volume, containing 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 10% glycerol, 1 mg of poly(dI-dC)-poly(dI-dC) (Amersham Biosciences, Piscataway, NJ, USA) and 0.4 mg/ml bovine serum albumin for 15 min at room temperature. The reaction mixture was then incubated with 50 F moles of a Cy5 5 0 -end-labeled double-stranded PTHrP P2 promoter wild-type oligonucleotide (sense strand: 5 0 -TCATTCCCGGCTCGGGGCTCCCCTCCACT CGCTCG-3 0 ; kB site is underlined) alone or with 25-fold excess of unlabeled wild-type or mutant P2 oligonucleotides for 15 min at room temperature. Samples were analyzed by electrophoresis using 4% nondenaturing polyacrylamide gels with 1 Â TGE buffer (25 mM Tris, 189 mM glycine and 1 mM EDTA) containing 5% glycerol. The gels were scanned with a Typhoon 9410
Variable Mode Imager (Amersham Biosciences) to detect the Cy5 fluorescence. Consensus NF-kB binding activity was measured using 5 mg of the nuclear extracts with 2 Â 10 4 c.p.m. of a 32 P-labeled oligonucleotide probe containing a kB site from class I major histocompatibility complex (MHC) promoter (5 0 -CAGGGCTGGGGATTCCCCATCTCCA CAGTTTCACTTC-3 0 ; kB site is underlined), as described previously. 30 For supershift experiments, 4 ml each of p50 (H-119; sc-7178), p50 NLS (sc-114), p65 (sc-109), c-Rel (sc-71), Bcl-3 (C-14; sc-185) antibodies (Santa Cruz, Santa Cruz, CA, USA) was incubated with 7.5 mg nuclear extract for 10 min at room temperature before the addition of buffers and oligonucleotides.
Chromatin immunoprecipitation-PCR and quantitative PCR
Chromatin immunoprecipitation (ChIP) was performed with antibodies against Bcl-3 (C-14), c-Rel (C) and p50 (H-119) using the ChIP assay kit (Upstate, Charlottesville, VA, USA). The specific sequence from immunoprecipitated and input DNA was detected by PCR using primers for PTHrP P2 promoter region: (forward, 5-GCCACCTCTTTGCGACTAGCT-3) and (reverse, 5-GGTTGGAGGCGAGTTGAAAAC-3). The annealing temperature was 581C and the amplicon size was 91 bp. Quantitative PCR monitored with SYBRGreen was performed using the ABI 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) as described previously. 31 Experimental ChIP-PCR values were normalized against values obtained by a standard curve constructed by input DNA (5-0.008%, fivefold dilution, R 2 40.99) with the same primer set. Quantitation of transcription factor binding was expressed as enrichment ratio of antibody over IgG control, and each error bar represents standard deviation calculated from triplicates.
Plasmids and site-directed mutagenesis
A human PTHrP P2-luciferase reporter gene construct was derived by cloning the human P2 promoter À1030 (SmaI) to À611 (Sau3A) fragment into pGL-2 basic vector (Promega, Madison, WI, USA). For site-directed mutagenesis, a SacI-ApaI restriction fragment from the human PTHrP P2 promoter was subcloned into the SacI-ApaI sites of pCR2.1TOPO plasmid (Invitrogen). The NF-kB site within the PTHrP P2 promoter was mutated by PCR-amplifying the entire PTHrP-P2/pCR2.1TOPO plasmid using the Expand Long Template PCR System (Roche, Indianapolis, IN, USA) and sense (5 0 -CTCACATCCACTCG CTCG-3 0 ) and antisense (5 0 -CACAGAGCCGGGAATGAG-3 0 ) oligonucleotides that contained the desired mutations (mutated nucleotides are underlined), as described previously. 32 A PCR product of appropriate size (B3.9 kb) was obtained. This PCR product was blunt-ended with T4 DNA polymerase (New England Biolabs, Ipswich, MA, USA), kinased with T4 polynucleotide kinase (New England Biolabs), circularized with T4 DNA ligase (New England Biolabs) and transformed into DH5a cells. Once clones containing the desired mutations were obtained and confirmed by DNA sequencing, the mutated P2 promoter was subcloned back into pGL2/PTHrP-P2/Luc plasmid.
Western blotting
Approximately 40 mg of the nuclear and cytoplasmic lysates were separated on a 12% Tris-glycine SDS-polyacrylamide gel electrolysis gel. Protein was transferred to a nylon membrane and then probed with primary antibodies specific for Tax (168A51-42; Tab 176; NIH AIDS Research & Reference Reagent Program), NF-kB p50 (Epitomics, Burlingame, CA, USA), p65, c-Rel, IkB-a, Bcl-3 (same as used in supershifts) and b-Actin (Sigma, St Louis, MO, USA) followed by incubation with goat antimouse or goat anti-rabbit (Promega) horseradish peroxidaseconjugated secondary antibodies. The signal was detected by chemiluminescence using Western Lightning Chemiluminescence Reagent Plus (PerkinElmer Life Sciences, Boston, MA, USA).
Transfections
To investigate the effect of NF-kB on PTHrP transcriptional regulation, NIH3T3 cells at 60% confluence were co-transfected with 1 mg of either wild-type pGL2/PTHrP-P2/Luc, mutant pGL2/ PTHrP-P2/Luc or pGL2 constructs in the presence or absence of expression vectors for NF-kB p50 (50-500 ng), p65 (500 ng), c-Rel (50-500 ng) or Bcl-3 (10-500 ng) using Lipofectamine Plus reagent (Invitrogen) and harvested after 48 h of transfection. pcDNA-3.1 was used as a 'filler' plasmid so that the total amount of DNA would be the same in all transfection groups. The plasmid pbgal-Control Vector (250 ng) was included in each transfection and served as an internal control to correct for transfection efficiency. Luciferase activity was measured with the Luciferase Assay System (Promega) using 40 ml of lysate. Simultaneously, b-galactosidase activity was measured with the Luminescent b-Galactosidase Detection Kit II (BD Biosciences, San Jose, CA, USA).
RT-PCR, Bay 11-7082 treatment and real time RT-PCR
Total RNA was extracted using TRIZOL reagent (Invitrogen). Approximately 2.5 mg of RNA was reverse transcribed with Superscript Reverse Transcriptase (Invitrogen). The cDNA was amplified with specific oligonucleotide primers for Bcl-3, and b2-microglobulin using Platinum Taq DNA polymerase (Invitrogen), as described previously. 33, 34 The PCR products were analyzed by electrophoresis on a 1% agarose gel. For Bay 11-7082 treatment, 2 Â 10 6 cells were treated with Bay 11-7082 (Alexis Biochemical Corporation, CA, USA) or vehicle control (dimethyl sulfoxide). To measure the total PTHrP and P2 promoter-initiated transcripts, 1 mg RNA was reverse-transcribed and submitted for real-time RT-PCR analysis using TaqMan Gene Expression assays (4331182 and 364171-B4 respectively; Applied Biosystems). b2M (4333766; Applied Biosystems) was used as a reference gene.
Statistical analysis
Pooled-variance t-tests were used to analyze the data from transfection assays. Analysis of variance (ANOVA) with Dunnett's tests was used to analyze the data from titration with p50, c-Rel, Bcl-3 and Bay 11-7082 treatment and vehicle control groups. Means and standard deviations are plotted in the figures. The mean differences and 95% confidence intervals are available upon request. A P-value of o0.05 was considered significant.
Results
Identification of NF-kB sites in the PTHrP P2 promoter
Following sequence analysis of the human PTHrP gene (described in the Materials and methods section), we identified two putative NF-kB binding sequences in the 5 0 -regulatory region beginning at positions À1558 to À1548 (GGAAATTCCC) and À152 to À142 (GGGGCTCCCC) nucleotides from the transcription start site for exon 3 ( Figure 1 ). These sites represented excellent matches to the 5 0 -GGGRNNYYCC-3 0 consensus NF-kB sequence. 35 Putative kB sites almost identical to the human PTHrP kB sites were also present in the mouse and the rat PTHrP promoter regions (Figure 1 ). The kB binding sequence (À1513 to À1503) was present in dog but the sequence proximal to the transcription start site (À152 to À142) was a partial consensus. In this study, we focused on the kB1 sequence (À152 to À142) due to its proximity to the transcription start site for exon 3 in the human PTHrP gene.
Tax and IkB-a expression in HTLV-1-infected T cells and ATLL cells
In resting cells, NF-kB is retained in the cytoplasm due to binding to specific NF-kB inhibitors of the IkB family. Following activation of cells by various stimuli, signal transduction cascades lead to the degradation of IkB-a and translocation of NF-kB into the nucleus. Since Tax is known to activate the NF-kB pathway, we measured the levels of Tax expression in various cell lines (Figure 2) . Three of the HTLV-1-infected cell lines (MT-2, SLB-1 and HT-1RV) have very high levels of Tax expression. In addition to the 40-kDa Tax band, a 69-kDa band, which is a fusion between the envelope and the Tax-coding sequence, is seen in MT-2 cells as described previously. 36 IMM-1 cells have a lower Tax protein expression compared to the other HTLV-1-infected cell lines. There was no detectable Tax protein expression in RV-ATL and MET-1 cells. A canine prostate carcinoma cell line, Ace-1, was used as a negative control for Tax. Also, in agreement with prior studies, 16 the protein level of IkB-a was significantly lower in three of the four HTLV-1-infected cell lines (SLB-1, MT-2 and HT-1RV) compared to ATLL cells (MET-1 and RV-ATL) (Figure 2 ). Imm-1 cells have a higher level of IkB-a protein compared to the other HTLV-1-infected cell lines, indicating a lower IkB-a turnover in these cells and likely lower NF-kB activation. These results suggested a direct relationship between Tax, IkB-a expression and NF-kB activity in T cells.
Constitutive NF-kB binding activity in HTLV-1-infected T-cell lines and ATLL cells
To measure the NF-kB binding activity in HTLV-1-infected and ATLL cells, nuclear extracts from these cells were subjected to electrophoretic mobility shift assays (EMSA) with a 32 P-labeled, double-stranded oligonucleotide probe containing a kB site from the class I MHC promoter. No NF-kB-specific protein DNA complexes were detected in HTLV-1-negative Jurkat T cells. In contrast, enhanced NF-kB binding activity was detected in the nuclear extracts from HTLV-1-infected T-cell lines and ATLL cells (Figure 3a, lanes 3-8) . The NF-kB binding activity in MT-2 and SLB-1 extracts consisted of a single complex (C1), while there were two complexes in MET-1, RV-ATL, HT-1RV and IMM-1 extracts (C2 and C3). The complexes in MT-2 cell extracts were composed predominantly of p50 and c-Rel as antibodies against p50 and c-Rel produced a shifted complex (Figure 3b, lanes 3, 4 and 6 ). The lower complex (C2) in MET-1, RV-ATL, HT-1RV and IMM-1 extracts consisted of p50/p50 (Figure 3b, lanes 3 and 4) . The upper complex (C3) in RV-ATL and IMM-1 extracts contained p50 and p65 (Figure 3b , lanes 3-5) while the HT-1RV extracts contained p50, p65 and c-Rel (Figure 3b, lanes 3-6) .
NF-kB binds to the sequences in the 5 0 regulatory region of PTHrP
To determine if the sequences in the PTHrP P2 promoter region were authentic NF-kB binding sites, a Cy5-labeled, doublestranded oligonucleotide probe spanning the putative NF-kB binding site was tested by EMSA for binding of NF-kB proteins (Figure 4) . A single complex (C1) formed in MT-2 and SLB-1 extracts, whereas two complexes (C2 and C3) formed in MET-1, RV-ATL, HT-1RV and IMM-1 extracts (Figure 4a) . The complexes in MT-2 cells were composed of p50 and c-Rel since antibodies specific to these proteins produced a supershift (Figure 4b, lanes 5, 6 and 8) . The lower complex (C2) in RV-ATL, HT-1RV, MET-1 (data not shown) and IMM-1 extracts Figure 1 Schematic representation of human, mouse, rat and dog PTHrP P2 promoter regions. The diagram illustrates the highly conserved nature of the NF-kB sequences in the PTHrP P2 promoter of humans, mice, rats and dogs. The NF-kB binding sequence in the human promoter studied in this report was found at À152 to À142 nucleotides upstream from transcriptional start site (indicated by arrows) in exon 3. Figure 2 HTLV-1 Tax expression was inversely proportional to IkB-a. Western blot analysis was performed on cytoplasmic (C) and nuclear (N) lysates from HTLV-1-infected and ATLL cells with antibodies against Tax and IkB-a proteins. Ace-1, a canine prostate carcinoma cell line was used as a negative control. b-Actin was used as loading control.
NF-jB regulates PTHrP MVP Nadella et al contained only p50. The upper complex (C3) consisted predominantly of p50 and c-Rel in HT-1RV extracts, while the complexes in RV-ATL, MET-1 and IMM-1 extracts did not supershift with antibodies to p50, p52 (not shown), p65, c-Rel, RelB (not shown) or Bcl-3. All of the above complexes formed specifically on the NF-kB binding site, since competition with an excess of unlabeled wild-type probe eliminated the complex (Figure 4b, lanes 3 ), but an excess of an unlabeled probe containing a mutated NF-kB site did not eliminate the complex (Figure 4b, lanes 4) . Additional complexes observed are nonspecific since they were out-competed by the mutated competitor.
ChIP demonstrated binding of NF-kB p50 and c-Rel to the PTHrP P2 promoter in vivo
To determine if NF-kB transcription factors bind to the PTHrP P2 promoter in vivo, we performed a ChIP assay with antibodies against p50, c-Rel and Bcl-3. IgG was used as a negative control. As shown in Figure 5a , the PTHrP P2 promoter was occupied by NF-kB p50 and c-Rel in MT-2 cells as measured by ChIP with real-time PCR quantification. As an additional measure, gel electrophoresis of the PCR product after a limited number of cycles gave an independent visual confirmation of the binding activity on the PTHrP P2 promoter (Figure 5b) .
Transactivation of the PTHrP kB site by the NF-kB family
To determine which NF-kB subunits transactivated the PTHrP kB site, expression plasmids for four kB proteins, p50, p65, c-Rel and Bcl-3, were co-transfected in NIH3T3 cells with either wildtype pGL2/PTHrP-P2/Luc, mutant pGL2/PTHrP-P2/Luc or pGL2 reporter plasmids. As shown in Figure 6a , expression of p65, c-Rel, Bcl-3 or Tax by themselves did not increase the expression of luciferase activity. Interestingly, p50 alone or in combination with c-Rel or Bcl-3 strongly transactivated the PTHrP P2 promoter. Mutation of the kB binding sequence significantly reduced luciferase activity compared to the wildtype, showing that the transactivation was occurring through the kB site. The effect of p50 and c-Rel were directly proportional to their concentration (Figures 6b and c) . Interestingly, the cooperative effect of Bcl-3 with p50 was inversely related to Bcl-3 concentration (Figures 6d and e) . While low levels of Bcl-3 cooperated with p50 in transactivating PTHrP, higher levels of Bcl-3 nullified the effect.
HTLV-1-infected T cells and ATLL cells expressed
Bcl-3 and other NF-kB family members p50 is known to transactivate genes in association with Bcl-3. Following our observations that p50 alone and p50/Bcl-3 upregulated PTHrP, we measured the levels of Bcl-3 expression in HTLV-1-infected and ATLL cells. As shown in Figure 7a , Taxexpressing cells have higher levels of Bcl-3 mRNA expression compared to the ATLL cells. To determine the subcellular localization of Bcl-3 and other NF-kB members in these cells, western blotting was performed on cytoplasmic and nuclear extracts (Figure 7b ). Cytoplasmic and nuclear fractions of MT-2, SLB-1, HT-1RV and IMM-1 cells had high levels of Bcl-3 protein.
In contrast, lower levels of Bcl-3 protein were present in MET-1 and RV-ATL cells, but it was predominantly localized in the nucleus. This was in agreement with the RT-PCR data. The presence of other NF-kB family members was confirmed by western blot analysis of the cytoplasmic and nuclear fractions, with b-actin serving as a loading control. p50 and c-Rel were present in similar amounts in all the cells, while p65 was expressed in the highest levels in SLB-1, MT-2, MET-1 and RV-ATL cells.
Inhibition of NF-kB by Bay 11-7082 decreased PTHrP mRNA expression in HTLV-1-infected T cells
Since NF-kB is constitutively activated in HTLV-1-infected T cells, we wanted to determine the effect of inhibition 0 -end-labeled double-stranded PTHrP P2 promoter wild-type oligonucleotide was analyzed by EMSA using 7.5 mg of protein from nuclear extracts of various cell lines. The complex formation is indicated as C1, C2, C3 and the specificity of binding was evaluated using a mutant -kB binding site as described in Materials and methods. The additional bands in the gel were not characterized and considered nonspecific (NS). (b) Antibody-mediated shift interference or supershifts were performed using 7-15 mg of protein from the nuclear extracts with specific NF-kB antibodies as indicated. of NF-kB on PTHrP expression. For this purpose, we used Bay 11-7082, a specific IkB phosphorylation inhibitor, which is known to reduce NF-kB activity. As shown in Figures  8a and c , inhibition of NF-kB activity by Bay 11-7082 significantly decreased PTHrP mRNA expression in MT-2 and SLB-1 cell lines at 3 and 6 h, respectively. Analysis of the promoter-initiated transcripts revealed that Bay 11-7082 reduced P2 promoter-initiated transcripts as expected (Figures 8b and d) . Bay 11-7082 treatment reduced PTHrP starting at 1 h following treatment (data not shown). Reduction of PTHrP expression occurred at higher concentrations (20 mM) and at a later time point (24 h) in RV-ATL cells (data not presented). Inhibition of NF-kB activity with PS-341, a potent proteasome inhibitor, inhibited PTHrP P2-promoter initiated transcripts and the total PTHrP expression in RV-ATL cells (data not shown). 
Discussion
PTHrP is expressed in a wide variety of tissues and is known to be dysregulated in several cancers. Increasing evidence suggests a role for PTHrP in proliferation and apoptosis besides its central role in the pathogenesis of HHM. 37 However, transcriptional regulation of this complex gene is poorly understood. In this study, we tested the hypothesis that the PTHrP gene is a direct target for NF-kB and report three major observations: (1) sequence, EMSA and competition analyses of the PTHrP P2 promoter sequences identified NF-kB binding sequences in the human PTHrP P2 promoter in vitro that was further confirmed as an authentic NF-kB binding site in vivo by ChIP assay; (2) NF-kB activated the human PTHrP P2 promoter in a subunit-specific manner as determined by an NF-kB overexpressing model in 3T3 cells; (3) inhibition of NF-kB by Bay 11-7082 in HTLV-1-infected T cell decreased P2 promoterinitiated transcripts.
The GC-rich PTHrP P2 promoter has been shown to be active in a variety of cells, including HTLV-1-infected and ATLL cells. 38 We identified two putative NF-kB-binding sequences in the human PTHrP P2 promoter that are located 1558 (kB2) and 152 (kB1) nucleotides upstream from the transcription initiation start site. Vasavada et al. 39 have shown that the SmaI/Sau3A fragment of the P2 promoter had significant activity in renal carcinoma cells. We identified and characterized the kB binding site (kB 1) within this fragment of the promoter. In addition, both the kB1 and kB2 sites are also present in the P2 promoter regions of mice and rats, although their order is reversed compared to humans. While the kB1 sequence appears to have two point mutations in the dog, the kB2 sequence is present and the location of both these elements is the same as in humans. The presence of these transcription elements across different species is consistent with the concept that NF-kB is important in modulating the expression of PTHrP.
Although tightly regulated in normal physiologic cellular responses, NF-kB is constitutively activated in various malignancies such as solid tumors, lymphomas and leukemias, including ATLL. 40 HTLV-1 Tax, in addition to mediating transcription from the viral promoter, activates numerous cellular genes by interacting with NF-kB, CREB/ATF, SRF and NF-AT pathways. Tax-mediated NF-kB activation is crucial for transformation of T cells by HTLV-1. 41 However, the presence of constitutively activated NF-kB pathway in ATLL cells, despite the lack of detectable Tax expression, suggests that Tax may be needed to initiate but not to maintain NF-kB activation. Although several studies have shown that Tax transactivates PTHrP, particularly the P3 promoter, [42] [43] [44] it is not clear whether Tax is required for PTHrP expression because ATLL cells that do not express detectable Tax have high levels of PTHrP. In this study, we have compared a variety of cell lines with different levels of Tax expression to understand the role of Tax and NF-kB in the regulation of PTHrP. In vitro-transformed MT-2 and SLB-1 cells express high tax and low PTHrP. ATLL cells (RV-ATL and MET-1) express PTHrP in the absence of Tax. HT-1RV cells, obtained by superinfecting RV-ATL cells with HTLV-1, express very high levels of Tax and low PTHrP. 45 Our newly developed in vitro immortalized cells (IMM-1) express low levels of Tax and moderate levels of PTHrP (data not shown). Our data are in agreement with previous studies where Tax-expressing T cells have a very low level of IkBa compared to ATLL cells (RV-ATL and MET-1) indicating that Tax significantly accelerated loss of I-kBa.
EMSA and competition analyses of the PTHrP kB1 sequence showed specific complexes formed between NF-kB transcription factors and P2 oligonucleotides in extracts from ATLL and the HTLV-1 cell lines tested. It is a well-known feature of NF-kB signaling that different NF-kB dimers can preferentially bind functionally distinct DNA-binding sites. Tax has been shown to activate the c-Rel gene and induce predominantly NF-jB regulates PTHrP MVP Nadella et al c-Rel-containing complexes. 46 Consistent with these observations, the complex formed in extracts from SLB-1 and MT-2 cells, which express high levels of Tax, contained p50 and c-Rel as the major DNA-binding components. This finding was confirmed by the presence of a similar complex with a known kB containing probe (from MHC class I gene promoter) in these cells. Interestingly, there were two distinct complexes in the ATL, HT-1RV and surprisingly even in IMM-1 cells. The lower complexes (C1) in extracts from ATL, HT-1RV and IMM-1 cells were composed of p50 alone. The upper complex (C2) in extracts from in HT-1RV cells was composed of p50/c-Rel, confirming our previous observation that Tax induces the formation of p50/c-Rel-containing complexes. On the other hand, the upper complex in extracts from ATL and IMM-1 cells is intriguing since it did not supershift with antibodies against p50, p65, c-Rel, Bcl-3, RelB (data not shown) or p52 (data not shown). Our attempts to identify these proteins by proteomics and mass spectrometry have been unsuccessful; therefore, the proteins in this complex remain unidentified. ChIP assays confirmed binding of NF-kB p50 and c-Rel on the PTHrP P2 promoter in vivo. Finally, the differences in the complexes formed in these cells potentially explain the differences in the level of PTHrP P2 promoter transactivation in these cells.
Our transfection studies showed that the human PTHrP P2 promoter can be activated in a subunit-dependent manner by p50/p50 alone, or by a combination of p50/c-Rel or p50/Bcl-3, but not by p65 or p50/p65. Most of the transcriptional effect was attributable to an intact NF-kB site as demonstrated by a significant decrease in luciferase activity in 3T3 cells transfected with constructs bearing a disrupted kB sequence. We were surprised by the activation of PTHrP by p50/50 alone since p50 does not have a transactivation domain. There have been conflicting reports regarding the role of p50/p50 in transcription. While some studies support the ability of p50 to transactivate, particularly in the presence of Bcl-3, others have shown that p50 homodimers act as repressors by binding kB sites that would normally be activated by p50/p65 heterodimers. Mori et al. 16 have shown that leukemic cells from ATL patients have abundant p50/p50 homodimers; however, p50 was not able to activate transcription from a p50/p65-inducible construct containing five repeats of a kB motif from the IL-2Ra gene. Interestingly, p50 homodimers are capable of binding all kB Quantitative real time RT-PCR was performed using primers specific for PTHrP all transcripts and PTHrP P2 promoter-initiated transcripts using TaqMan Gene Expression Assays. In MT-2 cells, Bay 11-7082 decreased (a) total PTHrP (b) and the P2 promoter-initiated transcripts in a dosedependent manner. In SLB-1 cells 11-7082 significantly decreased (c) total PTHrP and (d) the P2 promoter-initiated transcripts at 6 h of treatment. The data were normalized to b2-microglobulin (b2-M). Bars represent the mean7standard deviation of three independent samples (*Po0.05).
NF-jB regulates PTHrP
MVP Nadella et al binding motifs with similar efficiency but can probably transactivate only a subset of these such as those found in the Bcl-2 and H-2K genes. [47] [48] [49] It is possible that kB binding motifs like those found in Bcl-2, H-2K and PTHrP promoters may provide a sequence with which p50 forms an activating rather than a repressing complex. Evidence in support of this hypothesis was provided recently by Schreiber et al. 50 showing that p50 homodimers can interact with the RNA polymerase II at the promoters for genes such as CSF2, ICAM1 and TNF and likely maintain basal level of target gene activity in unstimulated cells. Alternatively, transcriptional activity of p50 may be cell type-dependent or dependent on undefined cofactors.
Although p50 and p52 have no defined transactivating domains, the association with Bcl-3 can lead to the conversion of these homodimers to positive regulators of gene expression. In addition, it has been shown that the formation of Bcl-3-p50 homodimer-DNA complexes depends on Bcl-3 concentration and phosphorylation. 51 Furthermore, it has been shown that Bcl-3 can increase the quantity of p50 homodimers that translocate to the nucleus. 52 In light of the observations that p50 activation can be induced by Bcl-3, we tested the possible association of Bcl-3 with p50 in transactivating PTHrP. First, we studied the expression of Bcl-3 in HTLV-1-infected and ATLL cells. Interestingly, Tax-expressing cells have higher levels of Bcl-3 compared to ATLL cells. Our data from transfection experiments have shown that a higher p50/Bcl-3 ratio resulted in activation of the promoter, while a lower p50/Bcl-3 ratio (higher concentrations of Bcl-3) resulted in a dramatic reduction of transactivation. This correlated well with our data where ATLL cells having lower Bcl-3 levels expressed high levels of PTHrP and Tax-expressing cells that had higher Bcl-3 levels expressed low levels of PTHrP. These data suggest that Bcl-3 may mediate its effect on PTHrP indirectly or at higher concentrations Bcl-3 dissociates from complexes with p50. Based on the results from Bcl-3 expression analysis and transfection assays, it is likely that the low level of Bcl-3 expression in ATLL cells contributed to the transactivation of the promoter while the high levels of Bcl-3 in Tax-expressing cells inhibited the promoter. This may help explain the differences in the transactivation of the PTHrP P2 promoter in ATL and Tax-expressing T cells.
Bay 11-7082 has been shown to be a specific NF-kB inhibitor by inhibiting the phosphorylation of the inhibitor IkB. 53 Treatment of HTLV-1-infected T cells not only reduced the P2 promoter-initiated transcripts but also total PTHrP expression providing additional support to our hypothesis that PTHrP is a direct target of NF-kB signaling. PS-341, a potent and selective proteasome inhibitor reduced NF-kB activity and total PTHrP expression and the P2 promoter-initiated transcripts in ATLL cells (data not shown). These results support a therapy for attempting to reduce NF-kB levels in ATLL patients.
In conclusion, our results support a direct role for NF-kB in the regulation of PTHrP. Since NF-kB is known to often mediate its effects through other transcription factors including AP-1, SP-1 and the Ets family of proteins and because binding sites for these factors and others exist within the P2 promoter, it will be important to establish the functional interaction between these factors and NF-kB in the regulation of PTHrP.
